Figure 3. Cost Effectiveness Acceptability Curves of A, Nivolumab + Ipilimumab Versus Avelumab + Axitinib; B, Nivolumab + Ipilimumab Versus Pembrolizumab + Axitinib; and C, Avelumab + Axitinib Versus Pembrolizumab + Axitinib.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.